BioAtla, Inc. (BCAB)
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
BioAtla, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 32.32M shares outstanding
USBioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers.
The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer.
Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
Leadership
Employees
41
Country
US
Sector
Healthcare
Website
bioatla.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Sievers Eric | Chief Medical Officer | Automatic Sell | 134 | $226.46 | Aug 31, 2026 |
 SHORT JAY M PHD | Chief Executive Officer | Automatic Sell | 259 | $437.71 | Aug 31, 2026 |
 Vasquez Christian | Chief Financial Officer | Automatic Sell | 71 | $119.99 | Aug 31, 2026 |
| Sievers Eric | Chief Medical Officer | Automatic Sell | 134 | $526.62 | May 31, 2026 |
| SHORT JAY M PHD | Chief Executive Officer | Automatic Sell | 259 | $1.0K | May 31, 2026 |
| Vasquez Christian | Chief Financial Officer | Automatic Sell | 82 | $322.26 | May 31, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
ACORN CAPITAL ADVISORS, LLC | 108.1K | 0.3% | 13F |
MILLENNIUM MANAGEMENT LLC | 70.6K | 0.2% | 13F |
 SHORT JAY M PHD Chief Executive Officer, Director | 52.0K | 0.2% | FORM 4 |
Lido Advisors, LLC | 16.7K | 0.1% | 13F |
Stonepine Capital Management, LLC | 16.4K | 0.1% | 13F |
ACADIAN ASSET MANAGEMENT LLC | 14.3K | 0.0% | 13F |
HRT FINANCIAL LP | 13.3K | 0.0% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 12.8K | 0.0% | 13F |
 Sievers Eric Chief Medical Officer | 11.3K | 0.0% | FORM 4 |
DEUTSCHE BANK AG\ | 10.6K | 0.0% | 13F |
Insiders
- Sievers EricChief Medical Officer
- SHORT JAY M PHDChief Executive Officer
- Vasquez ChristianChief Financial Officer
- WALDRON RICHARD AFormer Chief Financial Officer
- GRAY MARY ANNDirector
- Williams EddieDirector
- Smith Scott AndrewDirector
- MCBRINN SYLVIADirector
- STEINMAN LAWRENCEDirector
- Moran SusanDirector
based on 32.32M shares outstanding
US30d Avg
6.26K
60d Avg
45.07K
90d Avg
55.59K